Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

INTRODUCTION: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. METHODS: A possible disease-modifying effect of solanezumab was assessed using a new statistic...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Alzheimers Dement (N Y)
Päätekijät: Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2015
Aiheet:
Featured Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975050/
https://ncbi.nlm.nih.gov/pubmed/29854931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2015.06.006
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia